Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Issued Date
2024-01-15
Resource Type
ISSN
24058440
Scopus ID
2-s2.0-85180601831
Journal Title
Heliyon
Volume
10
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Heliyon Vol.10 No.1 (2024)
Suggested Citation
Assawakosri S., Kanokudom S., Suntronwong N., Chansaenroj J., Auphimai C., Nilyanimit P., Vichaiwattana P., Thongmee T., Duangchinda T., Chantima W., Pakchotanon P., Srimuan D., Thatsanathorn T., Klinfueng S., Sudhinaraset N., Wanlapakorn N., Mongkolsapaya J., Honsawek S., Poovorawan Y. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination. Heliyon Vol.10 No.1 (2024). doi:10.1016/j.heliyon.2023.e23892 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95547
Title
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence of booster vaccine‐induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed to determine the serological immune response of COVID-19 booster after CoronaVac-priming. Methods: A total of 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP), viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2, full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both binding and neutralizing antibodies against wild-type and Omicron was determined on day 90–120 after booster. Results: A waning of total RBD immunoglobulin (Ig) levels, anti-RBD IgG, and neutralizing antibodies against Omicron BA.1, BA.2, and BA.4/5 variants was observed 90–120 days after booster vaccination. Participants who received mRNA-1273 had the highest persistence of the immunogenicity response, followed by BNT162b2, AZD1222, and BBIBP-CorV. The responses between full and half doses of mRNA-1273 were comparable. The percentage reduction of binding antibody ranged from 50 % to 75 % among all booster vaccine. Conclusions: The antibody response substantially waned after 90–120 days post-booster dose. The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of humoral immune responses against the Omicron variant compared to the inactivated BBIBP booster. Nevertheless, an additional fourth dose is recommended to maintain immune response against infection.